ISAC Modulation of Tumor Microenvironments to Enable Durable Antitumor Immunity
2:45 pm - Wednesday 28th January 2026
- Characterizing the immune composition of preclinical tumor models and the therapeutic relevance to patient populations
- Understanding mechanism of action-dependent relationships between antigen density and treatment efficacy demonstrates potential ISAC advantages over conventional antibody-drug conjugates in clinical translation
- Tumor-targeted myeloid activation stimulates both innate and adaptive immune responses transforming immunologically cold tumors into hot microenvironments resulting in more durable responses
